{"id":"NCT04460183","sponsor":"Thirty Respiratory Limited","briefTitle":"A Study to Assess Efficacy and Safety of RESP301 Plus Standard of Care (SOC) Compared to SOC Alone in Hospitalized Participants With COVID-19","officialTitle":"An Open-label, Adaptive Randomized, Controlled Multicenter Study to Evaluate the Efficacy and Safety of RESP301 Plus Standard of Care (SOC) Compared to SOC Alone in Hospitalized Participants With COVID-19 WHO Grade 3&4 (NOCoV2)","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2020-07-29","primaryCompletion":"2021-04-24","completion":"2021-05-21","firstPosted":"2020-07-07","resultsPosted":"2022-06-02","lastUpdate":"2022-06-02"},"enrollment":19,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["COVID-19"],"interventions":[{"type":"DRUG","name":"RESP301, a Nitric Oxide generating solution","otherNames":[]},{"type":"OTHER","name":"Standard of Care","otherNames":[]}],"arms":[{"label":"Investigational arm","type":"EXPERIMENTAL"},{"label":"Control arm","type":"ACTIVE_COMPARATOR"}],"summary":"The effect of RESP301 as an add on treatment to SOC will be evaluated for its efficacy in reducing rate of progression to a more severe level of COVID-19 and for safety, by comparison with SOC alone in hospitalized COVID-19 patients.","primaryOutcome":{"measure":"Number of Participants Who Progress by at Least One Level Higher on the Modified WHO Ordinal Scale","timeFrame":"Baseline, Day 2 and Day 3","effectByArm":[{"arm":"RESP301+SoC","deltaMin":0,"sd":null},{"arm":"Standard of Care (SoC)","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":2,"countries":["United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":14},"commonTop":["Cough","Oropharyngeal Discomfort","Constipation","Headache","Oxygen Saturation Decreased"]}}